INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 441s ago
HOUSE PTR29m ago
SEC 13F29m ago
ROBINHOOD CHAIN29m ago
SEC FORM 4/Tax withholdingVerified data

Willoughby Scott B. reported SGMO

SVP, CHIEF LEGAL OFFICER, SECY · SANGAMO THERAPEUTICS, INC · Common Stock

Side
F
Value
$703
Shares
4,036
Price
$0.17
Executed
May 25, 2026
Disclosed
May 27, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 25 executedMay 27, 2026 disclosed

SGMO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

    $703 reported value · 0.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SGMO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    DN
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$703
    4,036 sh
    		May 25, 2026May 27, 2026
    traded May 25, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$284
    1,630 sh
    		May 25, 2026May 27, 2026
    traded May 25, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JN
    Jain NikunjPrincipal Accounting Officer
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$334
    1,919 sh
    		May 25, 2026May 27, 2026
    traded May 25, 2026
    		+2dSEC FORM 4

    Evidence

    34
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Open-market sale
    		SELL$18K
    69.8K sh
    		Apr 22, 2026Apr 23, 2026
    traded Apr 22, 2026
    		+1dSEC FORM 4

    Evidence

    41
    DN
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Open-market sale
    		SELL$89K
    345.9K sh
    		Apr 21, 2026Apr 23, 2026
    traded Apr 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Grant or award
    		A—
    225.0K sh
    		Apr 1, 2026Apr 3, 2026
    traded Apr 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JN
    Jain NikunjPrincipal Accounting Officer
    SGMOSANGAMO THERAPEUTICS, INC
    Grant or award
    		A—
    225.0K sh
    		Apr 1, 2026Apr 3, 2026
    traded Apr 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$2,406
    5,119 sh
    		Feb 25, 2026Feb 26, 2026
    traded Feb 25, 2026
    		+1dSEC FORM 4

    Evidence

    9
    DN
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$975
    2,063 sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DN
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$5,806
    12.4K sh
    		Feb 25, 2026Feb 26, 2026
    traded Feb 25, 2026
    		+1dSEC FORM 4

    Evidence

    9
    JN
    Jain NikunjPrincipal Accounting Officer
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$315
    666 sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JN
    Jain NikunjPrincipal Accounting Officer
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$2,406
    5,119 sh
    		Feb 25, 2026Feb 26, 2026
    traded Feb 25, 2026
    		+1dSEC FORM 4

    Evidence

    9
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$393
    832 sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Macrae SandyDirector, PRESIDENT, CEO AND DIRECTOR
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$41K
    103.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JN
    Jain NikunjPrincipal Accounting Officer
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$3,077
    7,721 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DD
    Davis Gregory DHead of Research & Technology
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$3,077
    7,721 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    13
    DN
    Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$15K
    36.7K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    13
    WB
    Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$15K
    36.7K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    13
    DP
    Duraibabu PrathyushaPRINCIPAL FINANCIAL OFFICER
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$15K
    36.7K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    9
    WB
    Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY
    SGMOSANGAMO THERAPEUTICS, INC
    Tax withholding
    		F$848
    2,035 sh
    		Nov 24, 2025Nov 26, 2025
    traded Nov 24, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001877368-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 25, 2026
    Published
    May 27, 2026
    Ingested by INSIDER
    Nov 5, 03:56 UTC
    Last re-read
    Nov 5, 03:56 UTC

    Extracted facts

    Filer
    Willoughby Scott B.
    Role
    SVP, CHIEF LEGAL OFFICER, SECY
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    SANGAMO THERAPEUTICS, INC
    Ticker
    SGMO
    Shares
    4,036
    Price per share
    $0.17
    Value
    $703
    Execution date (reported)
    May 25, 2026
    Owned after transaction
    647.4K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 4,036
    • Price: $0.1743

    = $703

    What this establishes

    Willoughby Scott B. filed this Form 4 reporting a tax withholding of SGMO on May 25, 2026. It became public on May 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, CHIEF LEGAL OFFICER, SECY
    Willoughby Scott B.cik:0001877368
    Issuer
    SANGAMO THERAPEUTICS, INCcik:0001001233

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for SGMO is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.